AU Patent

AU2017213886B2 — Humanized anti-CD3 antibodies, conjugates and uses thereof

Assigned to California Institute for Biomedical Research · Expires 2024-03-07 · 2y expired

What this patent protects

The present invention provides for humanized anti-CD3 antibodies and conjugates thereof. These conjugates may be useful in the treatment of conditions such as prostate cancer.

USPTO Abstract

The present invention provides for humanized anti-CD3 antibodies and conjugates thereof. These conjugates may be useful in the treatment of conditions such as prostate cancer.

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: AU2017213886B2
Jurisdiction: AU
Classification: —
Expires: 2024-03-07
Drug substance claim: No
Drug product claim: No
Assignee: California Institute for Biomedical Research
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.